Skip to Content

Windtree Therapeutics Inc WINT

Morningstar Rating
$5.68 +0.23 (4.28%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

WINT is trading at a 70% discount.
Price
$5.35
Fair Value
$78.72
Uncertainty
Extreme
1-Star Price
$187.46
5-Star Price
$8.92
Economic Moat
Kjd
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if WINT is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$5.45
Day Range
$5.005.90
52-Week Range
$4.7840.14
Bid/Ask
$5.51 / $5.70
Market Cap
$2.90 Mil
Volume/Avg
81,950 / 14,093

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
20

Valuation

Metric
WINT
Price/Earnings (Normalized)
Price/Book Value
0.54
Price/Sales
Price/Cash Flow
Price/Earnings
WINT

Financial Strength

Metric
WINT
Quick Ratio
1.08
Current Ratio
1.35
Interest Coverage
−411.32
Quick Ratio
WINT

Profitability

Metric
WINT
Return on Assets (Normalized)
−43.77%
Return on Equity (Normalized)
−201.75%
Return on Invested Capital (Normalized)
−161.62%
Return on Assets
WINT
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSqnlwqnkWsxt$557.8 Bil
VRTX
Vertex Pharmaceuticals IncHhxlcdxkwFsqlrp$103.3 Bil
REGN
Regeneron Pharmaceuticals IncKpkwcdyjLvfmdw$98.8 Bil
MRNA
Moderna IncQzxvbccpVglg$38.8 Bil
ARGX
argenx SE ADRHzpnklrLdp$21.3 Bil
BNTX
BioNTech SE ADRBykhzdfSnkcv$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncGlhbxrhlSqvqgs$18.4 Bil
BMRN
Biomarin Pharmaceutical IncNvptwpvRwzpd$17.5 Bil
RPRX
Royalty Pharma PLC Class AHstwkrdxcWqnykg$12.4 Bil
INCY
Incyte CorpXsqmybnhSvpqgs$11.9 Bil

Sponsor Center